



NDA 021321/S-034

SUPPLEMENT APPROVAL

Baxter Healthcare Corporation
Attention: Kristin Henney
Associate Director, Regulatory Affairs
32650 N. Wilson Road, WG1-3
Round Lake, IL, 60073

Dear Ms. Henney:

Please refer to your Supplemental New Drug Application (sNDA) dated May 25, 2016, received May 25, 2016, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Extraneal (icodextrin) Peritoneal Dialysis Solution.

This Prior Approval supplemental new drug application provides for the following revisions:

- addition of antibiotic compatibility information in **Section 12.3 Pharmacokinetics**;
- clarification to remove 'pre-existing' in the contraindication for severe lactic acidosis;
- revisions to section **5.3 Peritonitis and Encapsulating Peritoneal Sclerosis**, consistent with other peritoneal dialysis products;
- removal of language in **Warnings and Precautions** and **Adverse Reactions** considered nonspecific, duplicative or not believed to be plausibly related to Extraneal use.

APPROVAL & LABELING

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As at

<http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, please call Michael Monteleone, Associate Director for Labeling, at (301) 796-1952.

Sincerely,

{See appended electronic signature page}

Mary Ross Southworth, PharmD
Deputy Director for Safety
Division of Cardiovascular and Renal Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

ENCLOSURE(S):
Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

MARY R SOUTHWORTH
12/16/2016